+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel, Route of Administration, Drug Class, Formulation, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666179
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Non-steroidal Anti-inflammatory Drugs Market grew from USD 23.24 billion in 2024 to USD 25.06 billion in 2025. It is expected to continue growing at a CAGR of 7.63%, reaching USD 36.13 billion by 2030.

Setting the Stage for Advancements in Non-Steroidal Anti-Inflammatory Drugs

Non-steroidal anti-inflammatory drugs (NSAIDs) occupy a central role in pain management and chronic disease care, offering effective relief for millions worldwide. As global healthcare systems grapple with aging populations, rising incidences of arthritis and musculoskeletal disorders, and patient demand for non-opioid therapies, NSAIDs have become integral to therapeutic arsenals. This executive summary distills key insights into market dynamics, regulatory shifts, and competitive strategies, equipping stakeholders with a clear understanding of current trends and future possibilities.

The rising prevalence of inflammatory conditions and the consequent need for safe, accessible analgesics have spurred innovation across chemical classes and delivery platforms. Simultaneously, healthcare decision-makers emphasize cost containment, prompting manufacturers to streamline supply chains and optimize formulation portfolios. Regulatory authorities continue to update safety guidelines and approve novel COX-2 selective compounds, underscoring the delicate balance between efficacy and tolerability. Against this backdrop of clinical demand, policy evolution, and technological progress, this overview provides a structured lens through which to view the evolving NSAID landscape and identify actionable growth opportunities.

Revolutionary Trends Redefining the NSAID Market

The NSAID sector is undergoing a profound transformation driven by breakthroughs in molecular science, patient-focused therapies, and digital integration. Next-generation COX-2 inhibitors with improved cardiovascular safety profiles are entering clinical trials, promising to expand options for high-risk patient groups previously limited by adverse effects. Innovations in personalized medicine are enabling genotype-guided prescribing, reducing the trial-and-error approach to dosing. At the same time, digital health tools-ranging from mobile adherence trackers to remote monitoring platforms-are enhancing patient engagement and facilitating real-time outcomes measurement.

Concurrently, novel drug delivery technologies are redefining administration routes, rendering topical gels with enhanced skin penetration and rapid-release oral suspensions more viable. Regulatory agencies are placing heightened emphasis on post-market surveillance and environmental impact, which has led to greener manufacturing processes and waste reduction initiatives. As telemedicine gains traction, distribution networks are evolving to support direct-to-patient channels, expanding access while ensuring pharmacovigilance. These combined shifts are erasing traditional market boundaries and setting the stage for a new era of NSAID applications and business models.

Assessing the Ripple Effects of US Tariff Changes in 2025

In 2025, revised United States tariff policies are poised to reshape pharmaceutical supply chains and price structures for NSAID ingredients and finished dosages. Tariff increases on key raw materials imported from Europe and Asia have elevated production costs, compelling manufacturers to reassess sourcing strategies. Some companies are accelerating efforts to establish domestic synthesis facilities and formulate partnerships with local chemical producers, while others are renegotiating contracts to secure more favorable terms. The immediate impact has been an uptick in upstream expenses, which manufacturers have absorbed through process optimization and leaner operational models.

These tariff developments have also influenced pricing strategies downstream, where healthcare providers and payers face cost-containment pressures. Organizations that swiftly adapted by diversifying their supplier base have maintained competitive price points, whereas those reliant on single-source imports experienced margin compression. In response, several leading players have implemented tiered pricing and volume-based incentives to mitigate sticker shock for end users. Looking ahead, the evolving tariff landscape is expected to catalyze further localization of manufacturing and drive strategic alliances, fostering resilience against geopolitical uncertainties.

Deep Dive into Market Segmentation for Tailored Strategies

Understanding market segmentation is critical for stakeholders to craft targeted strategies and allocate resources effectively. In the realm of distribution channels, the dichotomy between over-the-counter and prescription pathways informs promotional tactics, regulatory obligations, and patient education initiatives. Oral, parenteral, and topical routes of administration each present unique pharmacokinetic considerations, necessitating distinct formulation approaches, labeling requirements, and clinician training. Molecular classification into COX-2 inhibitors and nonselective COX inhibitors further delineates safety profiles, reimbursement parameters, and competitive positioning.

Formulation diversity spans capsules, creams, gels, powders, suspensions, tablets, and transdermal patches, each designed to address adherence preferences, onset-of-action demands, and site-specific inflammation. The choice of delivery medium impacts shelf stability, manufacturing complexity, and cost of goods sold. Finally, end-user segmentation across hospital pharmacy, online pharmacy, and retail pharmacy channels dictates purchasing volumes, contracting frameworks, and distribution logistics. By integrating these segmentation lenses, companies can optimize product roadmaps, tailor marketing narratives, and anticipate shifts in prescribing behavior to capture emerging growth pockets.

Regional Dynamics Shaping the Global NSAID Arena

Regional nuances play a pivotal role in shaping the global NSAID narrative, as market dynamics diverge across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, strong generic penetration combined with a robust prescription drug infrastructure supports rapid adoption of efficacy-driven formulations. Regulatory pathways in North America emphasize rigorous clinical evidence and post-market safety monitoring, while Latin American markets exhibit accelerated growth fueled by expanding healthcare access and public procurement programs.

Within Europe, Middle East & Africa, price regulation and tender systems exert downward pressure on reimbursement rates, prompting manufacturers to pursue value-based contracts and real-world evidence initiatives. Emerging economies across the region are investing in local manufacturing to reduce dependency on imports and improve affordability. Meanwhile, the Asia-Pacific region is experiencing surging demand due to rising disposable incomes, increasing prevalence of chronic pain conditions, and growing digital health infrastructure. Governments in key Asian markets are streamlining approval processes for generics and novel formulations, encouraging domestic investment and cross-border collaborations.

Competitive Landscape and Leading Players Insights

The competitive landscape of the NSAID market features a spectrum of global pharmaceutical leaders, specialty innovators, and high-volume generics manufacturers. Established multinational corporations leverage expansive distribution networks and deep R&D investments to maintain leadership in branded COX-2 inhibitors, continually seeking label expansions and lifecycle management strategies. Mid-sized specialty firms focus on novel delivery systems and patient adherence solutions, targeting niche indications and leveraging real-world evidence to negotiate formulary placements.

Simultaneously, generic drug producers drive volume growth through cost leadership, often entering partnerships with regional distributors to maximize market penetration. Collaborations between brand companies and contract manufacturing organizations are intensifying, as capacity expansion and quality compliance become critical drivers of operational excellence. Across the board, mergers and acquisitions, joint ventures, and licensing agreements are prevalent, reflecting a strategic emphasis on pipeline diversification and geographic reach. Intellectual property expiries and biosimilars exploration further catalyze competitive dynamics, presenting both risks and opportunities for incumbent players.

Actionable Strategies to Navigate the Evolving NSAID Environment

To succeed in the evolving NSAID environment, industry leaders must adopt a multifaceted strategic approach. Strengthening supply chain resilience through dual sourcing and onshore manufacturing capabilities will buffer against geopolitical disruptions and tariff volatility. Investing in formulation innovation, particularly in rapid-release and targeted delivery platforms, can differentiate portfolios in saturated markets. Embracing digital engagement tools for patient education and adherence monitoring will enhance therapy outcomes and generate valuable real-world data for payers and regulators.

Engagement with healthcare stakeholders should extend beyond promotional activities to include collaborative evidence generation, value-based contracting, and pharmacovigilance partnerships. Companies should also integrate sustainability principles across operations, from green chemistry initiatives to circular packaging solutions, aligning with increasing environmental regulations and corporate responsibility agendas. Finally, continuous scanning of emerging markets for regulatory streamlining and unmet medical needs will unveil new growth corridors, enabling first-mover advantages in high-potential regions.

Rigorous Methodology Underpinning Our Analysis

Our analysis combines rigorous primary and secondary research methodologies to ensure robustness and reliability. We conducted in-depth interviews with key opinion leaders, senior executives, and formulary decision-makers to capture qualitative insights on clinical preferences, procurement behaviors, and emerging challenges. Secondary research encompassed peer-reviewed journals, regulatory filings, industry white papers, and proprietary databases, providing a comprehensive view of molecular developments, competitive dynamics, and policy landscapes.

Data triangulation techniques validated market segment definitions and regional trends, while quantitative modeling harnessed historical volumes and cost structures to identify performance drivers. A proprietary framework segmented the market along distribution, administration route, drug class, formulation, and end-user dimensions, enabling nuanced gap analyses and opportunity assessments. Internal quality control checkpoints, cross-functional expert reviews, and methodological audits ensured accuracy and consistency throughout the research process.

Synthesis of Key Takeaways and Future Outlook

The non-steroidal anti-inflammatory drugs market stands at a crossroads of scientific innovation, regulatory evolution, and commercial realignment. Transformative shifts in molecular design and digital health integration are converging with external pressures such as tariff changes and sustainability mandates, creating both challenges and avenues for growth. Stakeholders who align their product portfolios with patient-centric delivery solutions and robust evidence generation strategies will secure preferential access in increasingly competitive formularies.

Regional insights reveal that success requires adaptive approaches tailored to mature and emerging markets alike, while segmentation analysis highlights the importance of channel-specific engagement and formulation diversification. The competitive landscape underscores the value of strategic partnerships and agile business models, and the actionable recommendations outlined in this summary offer a roadmap to capitalize on evolving demand patterns. Collectively, these insights equip decision-makers with the clarity needed to navigate uncertainty and drive sustainable performance in the NSAID space.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Distribution Channel
    • Over The Counter
    • Prescription
  • Route Of Administration
    • Oral
    • Parenteral
    • Topical
  • Drug Class
    • COX-2 Inhibitors
    • Nonselective COX Inhibitors
  • Formulation
    • Capsules
    • Creams
    • Gels
    • Powders
    • Suspensions
    • Tablets
    • Transdermal Patches
  • End User
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Bayer Aktiengesellschaft
  • Johnson & Johnson
  • Novartis AG
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Over the Counter
8.3. Prescription
9. Non-steroidal Anti-inflammatory Drugs Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
9.4. Topical
10. Non-steroidal Anti-inflammatory Drugs Market, by Drug Class
10.1. Introduction
10.2. COX-2 Inhibitors
10.3. Nonselective COX Inhibitors
11. Non-steroidal Anti-inflammatory Drugs Market, by Formulation
11.1. Introduction
11.2. Capsules
11.3. Creams
11.4. Gels
11.5. Powders
11.6. Suspensions
11.7. Tablets
11.8. Transdermal Patches
12. Non-steroidal Anti-inflammatory Drugs Market, by End User
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Non-steroidal Anti-inflammatory Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Non-steroidal Anti-inflammatory Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Non-steroidal Anti-inflammatory Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Bayer Aktiengesellschaft
16.3.3. Johnson & Johnson
16.3.4. Novartis AG
16.3.5. GlaxoSmithKline plc
16.3.6. Teva Pharmaceutical Industries Ltd.
16.3.7. Sandoz International GmbH
16.3.8. Sun Pharmaceutical Industries Ltd.
16.3.9. Merck & Co., Inc.
16.3.10. Viatris Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NONSELECTIVE COX INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 40. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 44. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 49. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 75. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 80. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 85. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 90. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 95. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 105. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 110. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 115. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 120. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 125. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 130. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 145. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 150. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 160. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 165. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 170. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 177. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 181. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 186. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 191. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 211. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 221. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 236. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 238. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Non-steroidal Anti-inflammatory Drugs market report include:
  • Pfizer Inc.
  • Bayer Aktiengesellschaft
  • Johnson & Johnson
  • Novartis AG
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information